Pfizer Expects To Pay $772M To End Hormone Drug Suits

Law360, New York (May 13, 2011, 5:53 PM EDT) -- Pfizer Inc. said Thursday that it had resolved one-third of the suits filed over its hormone replacement therapy and that the drug company expected to spend at least $772 million to end all of the product liability fights.

The pharmaceutical giant has been hit with thousands of suits claiming it pedaled its hormone-replacement therapy drugs to menopausal women but neglected to warn them of cancer risks tied to the therapy.

Pfizer reported to the U.S. Securities and Exchange Commission on Thursday that it spent $172 million...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.